Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effectiveness of a commercial toothpaste that contains a new compound aimed at protecting a balanced oral microbiome in volunteers with periodontitis. This study is controlled and conducted across multiple centers, focusing on participants who regularly receive professional tooth cleaning every 3 to 6 months during periods without active treatment. The study aims to determine how well the toothpaste supports oral hygiene and potentially benefits oral microbial health. Participants will brush their teeth twice daily with the assigned toothpaste over a 3-month period, refraining from mouth rinsing after spitting. The toothpaste includes commonly used ingredients such as sodium fluoride and cleaning agents, along with a novel compound that may promote a healthy oral microbiome. This intervention period takes place between two professional tooth cleaning visits as part of a supportive periodontal therapy regimen. During the study, participants will be monitored for changes in oral health and the effectiveness of the toothpaste from enrollment until the end of the 12-week treatment. Assessments will include evaluation of oral microbial composition and dental health status. Researchers will also ensure participant safety and adherence to study procedures throughout the trial, which is expected to complete by the end of 2026.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two fixed-duration drug combinations for adults with previously untreated chronic lymphocytic leukemia CLL. This Phase 3 study compares sonrotoclax plus zanubrutinib against venetoclax plus acalabrutinib to see which therapy better controls the disease. The trial is sponsored by BeOne Medicines and focuses on treatment outcomes in this patient group. Participants receive either sonrotoclax and zanubrutinib or venetoclax and acalabrutinib, both given orally for a set period. After completing the drug regimen, participants enter an observation phase to monitor their health and disease status. The study uses a randomized, parallel design without masking, meaning participants are assigned to one of two treatment groups openly. During the trial, participants undergo regular assessments including imaging to measure disease size, evaluations of bone marrow and organ function, and monitoring for side effects. The primary outcomes include progression-free survival monitored for up to about 70 months and rates of undetectable minimal residual disease measured up to approximately 16 months. Secondary outcomes cover response rates, overall survival, adverse events, and quality of life scores. The total study duration extends to late 2031, allowing long-term follow-up and safety evaluation.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating whether systematic pelvic and para-aortic lymphadenectomy LNE improves overall survival in patients with stage I or II endometrial cancer who have a high risk of recurrence. The trial also looks at how LNE affects disease-free survival, quality of life, complications, side effects, and the number of lymph nodes removed. A total of 640 patients with specific histological types and stages of endometrial cancer will take part in this study. Participants will be randomly assigned to one of two groups. In Arm A, patients will undergo the standard surgical procedure including total hysterectomy and bilateral salpingo-oophorectomy, with an omentectomy added for certain cancer types. In Arm B, patients will receive the same standard surgery plus systematic pelvic and para-aortic lymphadenectomy reaching up to the left renal vein. The study compares these two surgical approaches. Throughout the study, participants will be monitored for overall survival over 60 months. Researchers will also assess disease-free and disease-specific survival at multiple time points up to five years. Serious complications will be recorded during surgery and follow-up visits. Quality of life will be evaluated regularly using standardized questionnaires. The number of lymph nodes removed will be documented during surgery to support the evaluation of treatment impact and safety.
Actively Recruiting
Researchers are evaluating whether a preference-oriented quality of life QoL monitoring system with specific diagnostic and therapeutic options can improve the well-being of patients with lung cancer during routine follow-up care. This study builds on successful QoL interventions for breast and colorectal cancer and aims to adapt the system for lung cancer patients in multiple centers. The study uses electronic QoL questionnaires and links patient data with a cancer registry to support analysis. Participants are randomly assigned to one of two groups. The intervention group receives real-time results from an electronic QoL monitoring system based on the EORTC QLQ-C30 and QLQ-LC29 questionnaires, along with access to a multiprofessional network of therapists such as pain therapy, psychotherapy, social support, nutrition counseling, physiotherapy, fitness, respiratory therapy, and palliative care. The control group also completes QoL assessments but neither patients nor their physicians receive the results however, the therapist network is available for both groups. QoL is assessed at study entry and monthly for six months. Throughout the six-month follow-up, participants complete QoL questionnaires at baseline and monthly intervals. Researchers monitor the proportion of patients needing QoL therapy based on a profile with eight dimensions, with a focus on whether the intervention reduces this need after six months. Data collection includes linking clinical information from a cancer registry. The study involves multiple assessments, therapeutic referrals, and ongoing monitoring to evaluate quality of life improvements in lung cancer patients.
Actively Recruiting
Researchers are evaluating whether combining re-radiochemotherapy Re-RCT followed by pembrolizumab immunotherapy improves overall survival compared to pembrolizumab alone, with or without chemotherapy, in adults with locoregionally recurrent PD-L1 positive head and neck squamous cell carcinoma HNSCC. This phase III randomized controlled trial focuses on patients whose tumors have a combined positive score CPS of at least 1 and who have previously received radiation therapy to the neck at least six months prior. Participants are assigned to one of two groups. One group receives re-radiochemotherapy with weekly cisplatin or carboplatin if kidney function is impaired followed by pembrolizumab immunotherapy administered intravenously every three weeks for up to two years. The other group receives pembrolizumab alone for up to two years, with the option of up to six additional cycles of cisplatin or carboplatin combined with 5-fluorouracil chemotherapy based on the treating physicians decision. During the study, participants will undergo regular visits and assessments including treatment administration, laboratory tests to monitor organ function and blood counts, and safety evaluations. The main outcome measured is overall survival over two years. Participants will be monitored throughout the treatment period and follow-up to assess treatment effects and safety. The trial is sponsored by Universitt des Saarlandes and will run until 2032.